These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 4744972)

  • 1. The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis.
    Meyrier A; Marsac J; Richet G
    Kidney Int; 1973 Aug; 4(2):146-53. PubMed ID: 4744972
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluoride and dialysis osteodystrophy: results of a double-blind study.
    Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA
    Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium carbonate. A better phosphate binder than aluminum hydroxide.
    Lerner A; Kramer M; Goldstein S; Caruana R; Epstein S; Raja R
    ASAIO Trans; 1986; 32(1):315-8. PubMed ID: 3535845
    [No Abstract]   [Full Text] [Related]  

  • 5. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
    Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
    Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypophosphataemia and osteomalacia in haemodialysis patients not taking phosphate binders.
    Ahmed KY; Varghese Z; Meinhard EA; Baillod RA; Skinner RK; Wills MR; Moorhead JF
    Adv Exp Med Biol; 1977; 81():581-90. PubMed ID: 899942
    [No Abstract]   [Full Text] [Related]  

  • 7. Controlled study of renal osteodystrophy in patients undergoing dialysis. Improved response to continuous ambulatory peritoneal dialysis compared with hemodialysis.
    Shusterman NH; Wasserstein AG; Morrison G; Audet P; Fallon MD; Kaplan F
    Am J Med; 1987 Jun; 82(6):1148-56. PubMed ID: 3605132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can renal bone disease be prevented?
    Shaldon S
    Proc Eur Dial Transplant Assoc; 1973; 10(0):91-123. PubMed ID: 4808119
    [No Abstract]   [Full Text] [Related]  

  • 9. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 11. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H; Koiwa F; Shishido K; Kinugasa E
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder.
    Malberti F; Surian M; Poggio F; Minoia C; Salvadeo A
    Am J Kidney Dis; 1988 Dec; 12(6):487-91. PubMed ID: 3143260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Osteodystrophy and calcinosis in chronic renal failure treated by repeated hemodialysis].
    Bagon J; Brunfaut C
    J Radiol Electrol Med Nucl; 1974 Jan; 55(1):35-9. PubMed ID: 4831994
    [No Abstract]   [Full Text] [Related]  

  • 15. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
    D'Haese PC; Spasovski GB; Sikole A; Hutchison A; Freemont TJ; Sulkova S; Swanepoel C; Pejanovic S; Djukanovic L; Balducci A; Coen G; Sulowicz W; Ferreira A; Torres A; Curic S; Popovic M; Dimkovic N; De Broe ME
    Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.
    Freemont AJ; Hoyland JA; Denton J;
    Clin Nephrol; 2005 Dec; 64(6):428-37. PubMed ID: 16370155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contrasting effects on bone histology of vitamin D and of calcium carbonate in the osteomalacia of chronic renal failure.
    Eastwood JB; Bordier PJ; Clarkson EM; Tun Chot S; de Wardener HE
    Clin Sci Mol Med; 1974 Jul; 47(1):23-42. PubMed ID: 4854694
    [No Abstract]   [Full Text] [Related]  

  • 18. The radiographic spectrum of renal osteodystrophy.
    Molpus WM; Pritchard RS; Walker CW; Fitzrandolph RL
    Am Fam Physician; 1991 Jan; 43(1):151-8. PubMed ID: 1986484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sevelamer hydrochloride and K/DOQI guidelines].
    Yumita S
    Clin Calcium; 2005 Sep; 15 Suppl 1():180-4. PubMed ID: 16279022
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.